Literature DB >> 7669491

Influence of metabolites on protein binding of verapamil enantiomers.

J A Johnson1, W S Akers.   

Abstract

This study investigated the effect of verapamil metabolites on R- and S-verapamil protein binding in plasma samples collected from subjects prior to rac-verapamil dosing and following single dose and steady state rac-verapamil dosing. In vitro studies of the effects of norverapamil, D617 and D620 on R- and S-verapamil protein binding were also performed. Protein binding of R- and S-verapamil was unchanged following single and multiple doses of rac-verapamil as compared with protein binding in pre-dose samples. In vitro, norverapamil had no effect on R- and S-verapamil protein binding up to 1000 ng ml-1. Norverapamil 5000 ng ml-1 caused a 30% increase in free fraction of both R- and S-verapamil. D617 and D620 concentrations up to 5000 ng ml-1 had no effect on R- and S-verapamil protein binding. We conclude the metabolites of verapamil have no clinically significant effect on R- and S-verapamil protein binding.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7669491      PMCID: PMC1365062          DOI: 10.1111/j.1365-2125.1995.tb04492.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  7 in total

1.  Stereoselective protein binding of verapamil enantiomers.

Authors:  A S Gross; B Heuer; M Eichelbaum
Journal:  Biochem Pharmacol       Date:  1988-12-15       Impact factor: 5.858

2.  Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis.

Authors:  J D Huang
Journal:  J Pharm Sci       Date:  1983-11       Impact factor: 3.534

3.  Factors affecting the plasma protein binding of verapamil and norverapamil in man.

Authors:  C L Yong; R L Kunka; T R Bates
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1980-11

4.  Verapamil protein binding in patients and in normal subjects.

Authors:  D L Keefe; Y G Yee; R E Kates
Journal:  Clin Pharmacol Ther       Date:  1981-01       Impact factor: 6.875

5.  Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism.

Authors:  H Echizen; B Vogelgesang; M Eichelbaum
Journal:  Clin Pharmacol Ther       Date:  1985-07       Impact factor: 6.875

6.  Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique.

Authors:  B Vogelgesang; H Echizen; E Schmidt; M Eichelbaum
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

7.  A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group.

Authors:  R Milroy
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  7 in total
  2 in total

Review 1.  Impact of stereoselectivity on the pharmacokinetics and pharmacodynamics of antiarrhythmic drugs.

Authors:  Reza Mehvar; Dion R Brocks; Majid Vakily
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis.

Authors:  P R Mayo; K Skeith; A S Russell; F Jamali
Journal:  Br J Clin Pharmacol       Date:  2000-12       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.